FIELD: medicine.
SUBSTANCE: declared group of inventions refers to medicine, namely to oncology, and can be used for treating B-cell tumour in a mammal. The method of treating B-cell tumour consists in administering a therapeutically effective amount of a pharmaceutical composition containing oligonucleotide having any of sequences SEQ ID NO: 1-9. Also, there are offered a method for inducing cell apoptosis of B-cell tumour, a method for increasing CD40 cell expression of B-cell tumour, and a method for inducing IL-10 cell production of B-cell tumour by contacting said cells of B-cell tumour with the composition containing oligonucleotide having any of sequences SEQ ID NO: 1-9. Besides, offered is the pharmaceutical composition containing (1) oligonucleotide having any of sequences SEQ ID NO: 1-9, and (2) a B-cell tumour agent.
EFFECT: invention provides effective therapy of B-cell tumour due to inducing tumour cell apoptosis which is caused by increasing CD40 cell expression of B-cell tumour and stimulated IL-10 cell production of B-cell tumour.
21 cl, 3 dwg, 5 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
OLIGONUCLEOTIDE OR ITS FUNCTIONAL HOMOLOG, COMPOSITION CONTAINING IT AND METHOD OF TREATING OF B-LYMPHOID NEOPLASM | 2006 |
|
RU2409672C2 |
TREATMENT OF B-CELLULAR MALIGNANT TUMORS USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR BY CHEMOTHERAPY AND RADIOTHERAPY | 2000 |
|
RU2305561C2 |
DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2423381C2 |
CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
COMBINATION OF CD19 ANTIBODY WITH BCL-2 INHIBITOR AND ITS APPLICATION METHODS | 2017 |
|
RU2756405C2 |
ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST | 2019 |
|
RU2788524C2 |
Authors
Dates
2011-03-10—Published
2006-02-13—Filed